Pharmacy and Pharmaceutical Sciences Commons^™

Advancements In Treatment For Sensorineural Hearing Loss: Implications For Rehabilitation Professionals, Shawn P. Saladin, Yasar Tasnif, Bianca Cruz, Robert B. Perez

JADARA

Rehabilitation professionals often work with individuals with sensorineural hearing loss. Sometimes the hearing loss is due to ototoxic medications that are prescribed as treatments for other conditions. An understanding of the types of ototoxic medications at the root of the sensorineural hearing loss combined with an understanding of the advancements in treatments will help the rehabilitation professional better serve consumers who fit this description.

Hybrid Nanocrystals For Treatment And Bioimaging Of Disease, Tonglei Li

Pharmaceutical Sciences Faculty Patents

Hybrid nanocrystals able to reach specific targets in the body for treatment and biological imaging are provided, as well as methods of making and administering same for treatment of disease conditions and for bioimaging and radiotherapy. The hybrid nanocrystals and methods can be used alone or in combination with other treatment and imaging modalities.

Microcystins As Agents For Treatment Of Cancer, Noel R. Monks, Shuqian Liu, Jeffrey A. Moscow

Pharmaceutical Sciences Faculty Patents

This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.

Comparing The 2013 Acc/Aha & 2014 Nla Dyslipidemia Guidelines And Their Impact On Clinical Decision Making, Alexander Forbes, Kevin Grimes, Jocelyn York, Laura Tsu

Pharmacy Faculty Articles and Research

This home-study CPE activity has been developed to educate pharmacists on the similarities and differences between the 2014 NLA Recommendations for Dyslipidemia Management and the 2013 ACC/AHA Guidelines for Treatment of Blood Cholesterol.

Bis-Pyridino Containing Compounds For The Use In The Treatment Of Cns Pathologies, Peter A. Crooks, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, Sangeetha Sumithran

Pharmaceutical Sciences Faculty Patents

N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.

Anti-Cocaine Compositions And Treatment, Donald W. Landry, Joanne Macdonald, Shi-Xiang Deng, Chang-Guo Zhan, Daquan Gao, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Victor Yang, Mei-Chuan Holden Ko, John J. Tesmer, Tien-Yi Lee, Young Min Kwon

Pharmaceutical Sciences Faculty Patents

Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.

Do Antibiotics Improve Outcomes For Patients Hospitalized With Copd Exacerbations?, Sagi Mathew, Deborah S. Zeitlin, Katherine Rickett

Scholarship and Professional Work – COPHS

EVIDENCE-BASED ANSWER

YES. Antibiotic use reduced mortality and treatment failure in patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) (strength of recommendation [SOR]: A, systematic reviews of randomized controlled trials [RCTs]).

Giving antibiotics early to hospitalized patients decreased the need for later ventilation and readmission within 30 days for exacerbation of COPD (SOR: B, a retrospective cohort study).

Agmatine And Agmatine Analogs In The Treatment Of Epilepsy, Seizure, And Electroconvulsive Disorders, Peter A. Crooks, Aimee K. Bence, David R. Worthen

Pharmaceutical Sciences Faculty Patents

Pharmaceutical preparations containing of agmatine, congeners, analogs or derivatives thereof for use in preventing or treating epilepsy, seizures and other electroconvulsive disorders are provided. Embodiments include administering an effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof to a human subject in need of treatment or prevention of epilepsy, seizure or other electroconvulsive disorder to treat, reduce, or prevent the disorder in the subject.

Compounds Of Use In The Treatment Of Epilepsy, Seizure, And Electroconvulsive Disorders, Peter A. Crooks, Aimee K. Bence, David Robert Worthern

Pharmaceutical Sciences Faculty Patents

The present invention provides pharmaceutical preparations and the uses thereof for preventing and/or treating seizures and other electroconvulsive disorders by administering a pharmaceutically effective amount of a therapeutic compound . . .

To view the rest of this abstract, please download this patent.

Methamphetamine: The New Epidemic, Jessica Gingery

Honors Capstones

Capstone submitted as a graduation requirement for the BSU Honors Program.

Chain-Modified Pyridino-N Substituted Nicotine Compounds For Use In The Treatment Of Cns Pathologies, Peter A. Crooks, Linda Dwoshin, Rui Xu, Joshua T. Ayers

Pharmaceutical Sciences Faculty Patents

Compounds for treating abuse of nicotinic receptor agonists, addiction to psychostimulant drugs, addiction to opiates, addiction to alcohol, addiction to tobacco products, addiction to nicotine, schizophrenia and related diseases, depression and related conditions, Alzheimer's disease, Parkinson's disease, irritable bowel syndrome, and colitis. The compounds competitively inhibit central nervous system acting nicotinic receptor agonists and act at the putative α3β2* and α4β2 neuronal nicotinic receptors in the central nervous system.

Cis-2,6-Disubstituted Piperidines For The Treatment Of Psychostimulant Abuse And Withdrawal, Eating Disorders, And Central Nervous System Diseases And Pathologies, Linda P. Dwoskin, Peter A. Crooks, Marlon D. Jones

Pharmaceutical Sciences Faculty Patents

Cis-2,6-disubstituted piperdine analogs, or lobeline analogs, having the general formula...

To see the remainder of this abstract, please download this patent.

Ritalin Use In Elementary School Children, Amber Ayres

Honors Capstones

Capstone submitted as a graduation requirement for the BSU Honors Program.

Bridged Nicotine Compounds For Use In The Treatment Of Cns Pathologies, Peter A. Crooks, Linda P. Dwoskin, Rui Xu, Vladimir P. Grinevich

Pharmaceutical Sciences Faculty Patents

Pharmaceutical compounds comprising bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at α3β2-containing nicotinic receptor subtypes, and compositions containing these compounds. The compounds and compositions are used to treat central nervous system pathologies.

Cis-2,6-Disubstituted Piperidines For The Treatment Of Psychostimulant Abuse And Withdrawal, Eating Disorders, And Central Nervous System Diseases And Pathologies, Linda P. Dwoskin, Peter A. Crooks, Marlon D. Jones

Pharmaceutical Sciences Faculty Patents

Cis-2,6-disubstituted piperdine analogs, or lobeline analogs, having the general formula:

To see the remainder of this abstract, please download this patent.

Morphine-6-Sulfate Analogues And Their Use For The Treatment Of Pain, Peter A. Crooks, Abdulghani A. Houdi, Santosh G. Kottayil, D. Allan Butterfield

Pharmaceutical Sciences Faculty Patents

3-O-Acetylmorphine-6-sulfate analogues are potent, centrally-acting morphine derivatives. The compounds are useful for the treatment of pain.

Use Of Lobeline Compounds In The Treatment Of Central Nervous System Diseases And Pathologies, Peter A. Crooks, Linda P. Dwoskin

Pharmaceutical Sciences Faculty Patents

Lobeline and nicotine evoke [³H]overflow from rat striatal slices preloaded with [³H]dopamine ([³H]DA). The lobeline-evoked overflow is calcium-independent and not antagonized by mecamylamine, suggesting a mechanism of action other than the stimulation of nicotinic receptors. Whereas nicotine stimulates nicotinic receptors, lobeline inhibits [³H]DA uptake into synaptic vesicles and striatal synaptosomes. The results suggest that different mechanisms are responsible for the increase in striatal DA release evoked by lobeline and nicotine. [³H]-Dihydrotetrabenazine [³H]DTBZ), used routinely to probe a high-affinity binding site-on the vesicular monoamine transporter (VMAT2) binds to vesicle …

The Common Cold: What Pharmacists Need To Know, Peggy Han, Peggy Mcmillan, Jeffery A. Goad

Pharmacy Faculty Articles and Research

A primer on the common cold for pharmacists, including its causes and pathophysiology and how to assess and treat patients.

Methods Of Treating Eye Conditions With Human Leukocyte Elastase (Hle) Inhibitory Agents, George A. Digenis, Charles Khouri

Pharmaceutical Sciences Faculty Patents

A method of reducing corneal scarring or fibroblast proliferation comprises applying to an area of a subject's eye afflicted with the condition a corneal scar-fibroblast proliferation-reducing amount of a free or polymer-bound HLE inhibitory agent under conditions and for a period of time effective to attain the desired effect. A method of reducing neovascularization of corneal scar tissue comprises applying to an area of a subject's eye afflicted with the condition a neovascularization-inhibitory amount of a free or polymer-bound HLE inhibitory agent under conditions and for a period of time effective to attain the desired effect.

Lobeline Compounds As A Treatment For Psychostimulant Abuse And Withdrawal, And For Eating Disorders, Peter A. Crooks, Linda P. Dwoskin

Pharmaceutical Sciences Faculty Patents

Methods are disclosed that suggest the use of lobeline and analogs thereof in treating individuals for drug dependence and withdrawal and for eating disorders.

Nornicotine Enantiomers For Use As A Treatment For Dopamine Related Conditions And Disease States, Peter A. Crooks, Linda Phyliss Dwoskin, Michael Thomas Bardo

Pharmaceutical Sciences Faculty Patents

Optically active nornicotine compounds as a treatment for dopamine-related conditions and disease states. Such disease states include the treatment of myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, eating disorders, ulcers, drug addiction and as a substitute for psycho-stimulant self-administration.

Nicotinic Receptor Antagonists In The Treatment Of Neuropharmacological Disorders, Peter A. Crooks, Linda P. Dwoskin, Alain Ravard

Pharmaceutical Sciences Faculty Patents

Nicotine analogs that have nicotinic receptor antagonist properties. These compounds have been shown to competitively inhibit dopamine release induced by nicotine. The nicotine analog compounds are useful in the treatment of nicotine abuse, smoking cessation therapy, as an antidote for nicotine intoxication, treatment of cognitive disorders such as Alzheimer's disease and for the treatment of Parkinson's disease.

Use Of L-Canavanine As A Chemotherapeutic Agent For The Treatment Of Pancreatic Cancer, Peter Crooks, Gerald A. Rosenthal

Pharmaceutical Sciences Faculty Patents

A pharmaceutical composition of canavanine, and a method treatment of cancer, particularly pancreatic cancer with L-canavanine is disclosed.

Outpatient Administration Of Paclitaxel, Siu Fun Wong

Pharmacy Faculty Articles and Research

Paclitaxel (Taxol®, Bristol-Meyers Squibb), anti neoplastic agent made from the bark of the Pacific yew tree, is undoubtedly one of the most exciting agents to be evaluated over the past decade. Paclitaxel has demonstrated significant promise against ovarian and metastatic breast cancer, and appears to be the most effective single agent to date for non-small-cell lung cancer in trials conducted by Eastern Cooperative Oncology Group (ECOG).